Tabarsi: Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form

Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form

Tabarsi et al., Iranian Journal of Pharmaceutical Research, doi:10.22037/ijpr.2021.115510.15401

Tabarsi et al., Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with.., Iranian Journal of Pharmaceutical Research, doi:10.22037/ijpr.2021.115510.15401

Sep 2021 Source PDF

Twitter
Facebook

All Studies Meta

Small 62 patient late stage RCT in Iran comparing favipiravir and lopinavir/ritonavir, showing significant improvement in fever, cough, and dyspnea with favipiravir on day 5. There was no significant difference in mortality, ICU admission, or chest CT improvement. IRCT20151227025726N14.

Important missing comments or errors? Let us know.

risk of death, 29.7% lower, RR 0.70, p = 0.70, treatment 3 of 32 (9.4%), control 4 of 30 (13.3%), NNT 25.

risk of ICU admission, 41.4% lower, RR 0.59, p = 0.36, treatment 5 of 32 (15.6%), control 8 of 30 (26.7%), NNT 9.1.

risk of <50% improvement in chest CT, 6.2% lower, RR 0.94, p = 0.76, treatment 24 of 32 (75.0%), control 24 of 30 (80.0%), NNT 20.

hospitalization time, 25.0% lower, relative time 0.75, p = 0.03, treatment 32, control 30.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Tabarsi et al., 30 Sep 2021, Randomized Controlled Trial, Iran, peer-reviewed, 27 authors, study period 4 April, 2020 - 7 May, 2020, average treatment delay 7.0 days, this trial compares with another treatment - results may be better when compared to placebo.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Abstract: Iranian Journal of Pharmaceutical Research (2021), 20 (4): 1-8 DOI: 10.22037/ijpr.2021.115510.15401 Received: May 2021 Accepted: September 2021 Original Article Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form Payam Tabarsia , Hossein Vahidib, Ali Saffaeic, Seyed Mohammad Reza Hashemiand, Hamidreza Jammatid, Bahram Daraeie, Arash Mahboubif, Farzad Kobarfardg, Majid Marjania, Afshin Moniria, Zahra Abtahiana, Atefeh Abedinid, Alireza Eslaminejadd, Jalal Heshmatniad, Maryam Sadat Mirenayatd, Atefeh Fakhariand, Sharareh Seifid, Mohsen Sadeghid, Alireza Dastanh, Sara Haselid, Seyed Alireza Nadjii, Raha Eskandarid, Sahar Yousefiand, Mohammad Varahramd, Alireza Zalij, Ali Akbar Velayatik and Farzaneh Dastand, l* Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. bDepartment of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. cStudent Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. dChronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. eDepartment of Toxico/Pharmacology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. f Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. gDepartment of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hErnest and Julio Gallo Management Program, School of Engineering, University of California, Merced, CA, United States. iVirology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. jFunctional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. kTracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. lDepartment of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. a * Corresponding author: E-mail: fzh.dastan@gmail.com Tabarsi P et al. / IJPR (2021), 20 (4): 1-8 Abstract Coronavirus disease -19 (COVID-19) pandemic, caused by SARS-CoV-2, has gradually spread worldwide, becoming a major public health event. This situation requires designing a novel antiviral agent against the SARS-CoV-2; however, this is time-consuming and the use of repurposed medicines may be promising. One such medicine is favipiravir, primarily introduced as an anti-influenza agent in east world. The aim of this study was to evaluate the efficacy and safety of favipiravir in comparison with lopinavir-ritonavir in SARS-CoV-2 infection. In this randomized clinical trial, 62 patients were recruited. These patients had bilateral pulmonary infiltration with peripheral oxygen saturation lower than 93%. The median time from symptoms onset to intervention initiation was..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit